Shuhua Liu

Dr. Shuhua Liu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in Renal Failure
Verified
Journal Article
Open access
RWRuolin Wang
Ruolin Wang
SSSiheng Shen
Siheng Shen
LJLuyong Jian
Luyong Jian
SLShuhua Liu
Shuhua Liu
QYQi Yuan
Qi Yuan
RHRenfa Huang
Renfa Huang
This study aimed to investigate the regulatory role of autophagy in acute kidney injury (AKI) induced acute lung injury (ALI).The male Sprague–Dawley rats were divided into four groups: normal sali...

19 October 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
SLShuhua Liu
Shuhua Liu
RWRuolin Wang
Ruolin Wang
CLChenhaoyu Liu
Chenhaoyu Liu
JHJiachun Huang
Jiachun Huang
XLXiaoyun Li
Xiaoyun Li
LWLei Wan
Lei Wan
Postmenopausal osteoporosis (PMOP) is associated with estrogen deficiency and oxidative stress (OS), which impair osteoblast survival and osteogenic function. Formononetin (FMN) is a phytoestrogen with antioxidant properties, but its protective effects on osteoblasts under OS and the signaling pathways associated with these effects remain incompletely understood. Here, we evaluated the effects of FMN in ovariectomized (OVX) mice and in a tert-butyl hydroperoxide (t-BOOH)-induced oxidative injury model in MC3T3-E1 cells. Bone microarchitecture, histology, serum OS markers, cell viability, reactive oxygen species (ROS) production, apoptosis, mitochondrial morphology, and osteogenic differentiation were assessed. Network pharmacology, molecular docking, molecular dynamics simulations, RNA sequencing, Western blotting, and pharmacological pathway-modulation experiments were used to investigate signaling changes associated with FMN treatment. FMN attenuated trabecular bone deterioration and systemic oxidative imbalance in OVX mice. In MC3T3-E1 cells, FMN improved cell viability, reduced ROS accumulation and apoptosis, alleviated mitochondrial damage, and preserved osteogenic differentiation following t-BOOH exposure. FMN treatment was accompanied by reduced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2), p38, and c-Jun N-terminal kinase (JNK), together with reduced expression of activator protein 1 (AP-1)-related proteins, including c-Fos, c-Jun, and phosphorylated c-Jun. Pharmacological reactivation of p38/JNK signaling with anisomycin attenuated several antioxidant, anti-apoptotic, and pro-osteogenic effects associated with FMN treatment, whereas nuclear factor erythroid 2-related factor 2 (NRF2) inhibition partially diminished FMN-mediated protection. Collectively, these findings support an association between the protective effects of FMN and modulation of mitogen-activated protein kinase (MAPK)/AP-1 and NRF2-associated signaling.